Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Gap fill = $1.58
Wook...watch $1.33. If (when?) we can close above that, we have a pattern that looks almost like the carbon copy of July-August of this year.
Javier.........December 12th: Guadalupe?
Will Bavi possibly assist Chemo in working more effectively inside the microenvironment?
TIA.
goodJohnhunting....I'll own up to not having the best of scientific minds. What's the difference?
Could this morning's PR possibly be a hint that the coding review is going well?
God bless ya, nh. St. Peregrine, ora pro nobis.
Truly appreciate your post, entdoc.
I've got family with cancer problems and I have told them to hang on....help was on the way. PPHM management has been cruel to shareholders and cancer victims.
You R a prince among men. Good luck to you.
Thanks, Krakonos. As I said. Today is a VERY low point for me. In since late 1999. NOTHING this company has promised has ever entered the world of reality.
That being said, I'll probably be back in at a certain point. I watch TA very carefully. But it'll be at a higher price than when I sold. That's the vicissitude of TA.
Doesn't it bother anyone that after more than a decade we have no drug even close to market? Can anyone say COTARA???!!
STOP with imaging, ISTs. NOTHING this company enunciates has EVER come to fruition.
STOP the insanity!
Sorry. Divested all my shares today and took it up the a$%. AGAIN! Vodka talking. After it all, I still believe in the science.
Another 3rd party screw-up with the Google debacle.
The Fund 2011: I just don't see why short sellers "love" this stock. There are a lot more lucrative short candidates out there than a stock which has lost more than 90% of its value in the last month.
Bungler: a question which may reveal my scientific ignorance, but what they hey.
You said:"Again, I repeat: The September 24 PR DID NOT state that the September 10 disclosure should not be relied on. It stated only that the clinical data disclosed on or before September 7 should not be relied on. The overall results reported on September 10 are not "clinical data" but are overall results."
The question: But aren't the overall results announced in the September 10th disclosure based on the pre-September 7th clinical data?
TIA for any clarification.
I've always said that I've never seen a message board with such brilliant and charitable contributors (in terms of their willingness to offer their insights and sacrifice their time to write them out for others). The past few days have witnessed heroic efforts by CP, keep_trying, FTM, Bungler and others to attempt to explain the unexplainable. I thank all of you.
At this point, I believe that the law of Ockham's Razor is the safest path (one should accept simpler theories until more complex ones become relevant). Given management's past track record of possessing the unique ability to grasp defeat from the jaws of victory, I think it's time to accept the simplest answer: management has either screwed up again or they've been outplayed by BP. Wall Street may well form an irrevocable conclusion (fair or unfair in this latest instance) that management at PPHM is either incredibly incompetent or incredibly stupid (or both). It's doubtful that they will ever again summon trust from big money again.
I know that they were blind (by procedural design) to the coding labeling debacle, but the fact is that this happens so very rarely that, given PPHM's management's previous track record, the fact that it happened to Bavi simply cements the perceptions of the company and it's management.
Comparison's have been made to VRTX with a similar problem from which they recovered. The difference there is that the VRTX management already had gained the confidence of Wall Street. To this point, we were told how long ago that cotara would be in Phase III development (after a methodological dosing delay which cost at least a year)? Still: nothing. ISTs, imaging -- all mentioned as fantastic future possibilities: but with this company it's ALWAYS been about FUTURE possibilities. And just when we're about to complete a supposedly air tight Gold Standard Phase II, we STILL screw up. (And if you cannot invest with relative confidence in that arena, how can you invest in anything this management oversees?)
I do still believe in the science. There have been too many accounts of the future of cancer drug immunological mechanisms (and we've got so many patents sewed up in that area that we'd have years of a head start on the rest of pharma). That's the tragedy.
I haven't sold any shares (and my purchases over the past couple of months or so have left me with an even larger position than I had before -- and thus an even bigger loss), and now I'll hold out until the company is sold for pennies of what should have been the shareholder reward for their $ and their patience. I'll watch management make tens of millions while so many retail investors are again left out in the cold because of those very people who will reap the reward of our financial losses.
I hope I'm wrong, not just for my sake but for all of the magnificent people who have contributed so selflessly and constructively over the past 12 years. But until I'm proven to be wrong, I think Ockham's Razor is the safest assumption.
swg_tdr and PGG76109: Thank you for your messages. Sorry I haven't been checking my Mailbox recently.
Sean
basketball....just out of curiosity: from whom/where did you get your alleged information about a press release coming from PPHM?
basketball....do you really think that 124 million shares in the last 2 days was RETAIL buying?
entdoc, R U really saying that when they cancelled the CS Conference they didn't know about this third party situation?
I find that very difficult to believe.
And IF they did know, they lied to us -- certainly far from ethical.
I haven't sold any of my recently reacquired shares because I don't know what the hell is really going on. However, I believe that the company's withdrawal from the CS conference and the reasons they gave for doing so were outright lies to investors. What were they thinking??!!
The IR man should be sued personally -- as should Steve King.
What really churns my blood is that the cancellation of the CS Conference was obviously a response to this development. Management lied through their teeth to us as to the reason -- and then decided to release it BEFORE market open on a Monday morning with the market already selling off.
I've always said this management is NOT retail shareholder friendly, and their handling of this situation just proves the point.
I agree with Thurly -- even if this development doesn't affect the bottom line test results, it'll be a couple of years before re-verification. And management will need to be changed. Regardless of whose fault, credibility needs to be re-established.
geo...most worried about that $30 million loan.
Questions:
(1) Are people in the various trials living longer?
(2) We were speaking last week that MOS had not yet been achieved. Even if the Group Coding data has been screwed up, does that affect MOS?
(3) Have there been complete recoveries?
Isn't something like this rather unusual? Hate to be a conspiracy nut, but I wouldn't rule out sabotage.
CP, I disagree, respectfully with your observation about not affecting Bavi results; I think the press release says differently:
In the meantime, investors should not rely on clinical data that the company disclosed on or before September 7, 2012 from its Phase II bavituximab trial in patients with second-line non-small cell lung cancer or any presentations or other documents related to this Phase II trial.
The most depressing sentence of the press release:
In the meantime, investors should not rely on clinical data that the company disclosed on or before September 7, 2012 from its Phase II bavituximab trial in patients with second-line non-small cell lung cancer or any presentations or other documents related to this Phase II trial.
Miss Sierra will be renowned as a seer or else she's about to get seared:
http://sierraworldequityreview.blogspot.com/2012/09/is-peregrine-pharmaceuticals-pphm.html
A little perspective:
the 20 day moving average: $2.86
the daily pivot price: $2.43
The stock price has gotten ahead of itself; it's in the process of consolidating at lower prices so it can advance. I'm not saying that the PPHM share price will fall to the 20 SMA (though it could if the market sells off). If the price continues to hold in the mid 3's, the 20 day will rise.
I know these sell offs are not what we like to see. BUT, believe me: it's better than going parabolic without a sufficient catalyst. Some got in this stock because of that Sierra character touting an announcement of Roche being announced as a partner yesterday. Didn't happen. Those people are probably leaving.
Sean
I think some are hesitant to buy here because this market is ripe for a sell-off and they want to see how PPHM acts should that occur. I think, however, that PPHM moves north well in market declines.
JR, I think we're getting close to that buy we're looking for.
JR, isn't $1.81 or so 50% Fibonacci retracement?
Cloaked:
$2.22 was the 50 EMA on the MONTHLY chart.
At the trend line, bids 15:1 ratio over the ask and the price doesn't move. MM games: someone wants shares.
11:10am: trend line holding. At this moment, bids over ask at an almost 6:1 ratio.
sunstar, I can only tell you you're wrong. I am not a short. I've been waiting for a pullback to buy heavily. I could kick myself that I didn't risk another $4000 when it hit its lows (after all, I'd already lost $55K because I was convinced of the science).
This pullback is, as JR says, a healthy consolidation.
Much better traders than me (volgoat, swingtrader, johnnyrocket, etc.) I think will agree that pullbacks to test trend lines are not a bad thing. I've been waiting for this to load up to levels where I had been. The sell offs are scary -- and articles which are meant to frighten are real downers. But they serve as catalysts to accomplish where the technicals want to go. JMHO.
Would not be surprised (nor a bad thing) to test the upward sloping trend line from early July at around $2.25
PPHM has bounced off an upwardly rising lower trend line several times in the past couple of days. So far, so good. A close below about $1.635 on a 15 minute bar would indicate a break below the trend line which stretches back to July 20th.
FWIW: Bollinger bands very tight on the Hourly chart, probably indicating a relatively good size move in the not-too-distant future. My gut says "down" would be a healthy consolidation process (also biotech and pharmaceuticals have been hiding out places for traders during the market down trend and if this market has legs per this morning's futures, these sectors may see short term money going to greener fields for awhile). On the other hand, the 200 day weekly moving average looms at $2.07.
The monthly charts speak for themselves. JAKE has provided a weekly chart and shows we're do for a pullback (which we need for a steady healthy chart pattern).
http://tinyurl.com/br4mws5
Hey JR, I made some $ back, but I'm still $50 K in the hole. However, the technicals are setting up to support a BIG run. I'm still looking for a significant pullback to shake out some impatient traders. I'll add more -- much more -- if the charts continue to hold up.
FWIW: The Weekly Pivot is $1.66. That's exactly where the downdraft hit this morning and bounced.
If we're in a new paradigm, weekly charts may be a better technical gauge than the dailies.